Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
Christoph A. Fink(Heidelberg University), Stefan A. Koerber(German Cancer Research Center), Jakob Liermann(Heidelberg University), Matthias Gückenberger(University Hospital of Zurich), Carolin Buchele(Heidelberg University), Lukas Baumann(Statistics Austria), D. Bonekamp(German Cancer Research Center), A. Lentz-Hommertgen(Heidelberg University), Claus Belka(LMU Klinikum), Michael Reiner(LMU Klinikum), Sebastian Klüter(Heidelberg University), Nicolaus Andratschke(University Hospital of Zurich), Juliane Hörner‐Rieber(Düsseldorf University Hospital), Jonas Ristau(Heidelberg University), E. Sandrini(Heidelberg University), Jürgen Debus(Heidelberg University), Philipp Hoegen-Saßmannshausen(German Cancer Research Center), Minglun Li(University of British Columbia), Michael Baumgartl(University of Zurich), H Schlemmer(German Cancer Research Center), Stefanie Corradini(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 4
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
|Journal of the American Society of Nephrology|2017|302